Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
Daiichi Sankyo Espha said on December 10 that its authorized generics (AGs) of the anticoagulant Xarelto (rivaroxaban) have earned an additional pediatric indication for the treatment of venous thromboembolism (VTE) and the prevention of recurrent VTE. The approval was granted…
To read the full story
Related Article
- Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- Xarelto AG Logs 9.6 Billion Yen on NHI Basis in April-September: Qol
November 10, 2025
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
- Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
BUSINESS
- Astellas’ Protein Degrader Setidegrasib Enters PIII in US
April 1, 2026
- Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
- Kyorin Exercises Option for BIODOL’s Pain Drug Candidate
April 1, 2026
- UCB Japan Files Zilbrysq Autoinjector in Japan
April 1, 2026
- Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…